Tetrahydroisoquinoline derivatives as LHRH antagonists
申请人:Abbott Laboratories
公开号:US05981521A1
公开(公告)日:1999-11-09
Tetrahydroisoquinoline derivatives of the formula: ##STR1## or a pharmaceutically acceptable salt, ester, or prodrug thereof, having activity as an LHRH antagonist, as well as pharmaceutical compositions containing the same, and methods for their use and preparation.
Ring enlargement of 1-cyclopropyl and 1-(trans-2′-phenyl cyclopropyl)tetrahydroisoquinoline N-oxide derivatives
作者:T.Samuel Bailey、John B. Bremner、David C. Hockless、Brian W. Skelton、Allan H. White
DOI:10.1016/0040-4039(94)85232-4
日期:1994.4
Thermolysis of the 1-(2′-phenylcyclopropyl)tetrahydroisoquinolineN-oxidederivative 3b in butyronitrile/mesitylene gave the 1,3,4,5-tetrahydro-2,3-benzoxazepine derivative 4b and the 2,3,5,6-tetrahydro-10,11-dimethoxy-3-methyl-5-phenyl-1H-4,3-benzoxazecine 5b, the first representative of the 4,3-benzoxazecine system, in low yield. The structure of 5b was confirmed by X-ray crystallography. Thermolysis
TETRAHYDROISOQUINOLINE DERIVATIVES AS LHRH ANTAGONISTS
申请人:ABBOTT LABORATORIES
公开号:EP1129076A1
公开(公告)日:2001-09-05
PHARMACOLOGICAL AGENTS FOR TREATING OCULAR DISEASES
申请人:CALASIA PHARMACEUTICALS, INC.
公开号:US20210154213A1
公开(公告)日:2021-05-27
Methods of treating presbyopia or cataract in a subject in need thereof are provided. The methods require administering to the subject an effective amount of a composition comprising a compound that inhibits the formation of high molecular weight aggregates of human α-A-crystallin. Compositions containing certain compounds are believed to be also effective in the treatment of transthyretin (TTR)-associated amyloidosis and Parkinson's disease.